Dr. Gilles J. A. Gallant is Founder and Principal Consultant of GG Biotech Consulting LLC, where he advises biotechnology and pharmaceutical companies on oncology drug development strategy and execution across all stages of development.

Previously, he served as Chief Development Officer at Mythic Therapeutics and as Senior Vice President and Global Head of Oncology Development at Daiichi Sankyo, where he led the development and global approval of Enhertu® and multiple antibody-drug conjugate (ADC) programs. Earlier, he held leadership roles at Bristol Myers Squibb, Human Genome Sciences, and BioMarin Pharmaceutical, contributing to several major oncology drug approvals.

Dr. Gallant serves on multiple advisory boards, including Bicycle Therapeutics and Iteru Systems, and is an active member of leading scientific organizations, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO).

He earned his PhD in medicinal chemistry and a bachelor’s degree in pharmacy from the Université de Montréal and was named a Fellow of the Ordre des Pharmaciens du Québec. He currently serves as a member of the MBrace Therapeutics Scientific Advisory Board.